Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA018-ADC in Patients with Advanced Solid Tumors

Next Previous
Trial Profile

A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA018-ADC in Patients with Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FDA018-ADC (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Most Recent Events

  • 10 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 04 Jun 2024 Results(As of October 8, 2023, n=62 pts) assessing safety and efficacy in patients with advanced solid tumors, mainly in triple negative breast cancer (TNBC), presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 10 Jan 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top